Search results for "KRAS"

showing 10 items of 232 documents

Integrative genomic and proteomic analyses identify targets for Lkb1 deficient metastatic lung tumors

2010

SummaryIn mice, Lkb1 deletion and activation of KrasG12D results in lung tumors with a high penetrance of lymph node and distant metastases. We analyzed these primary and metastatic de novo lung cancers with integrated genomic and proteomic profiles, and have identified gene and phosphoprotein signatures associated with Lkb1 loss and progression to invasive and metastatic lung tumors. These studies revealed that SRC is activated in Lkb1-deficient primary and metastatic lung tumors, and that the combined inhibition of SRC, PI3K, and MEK1/2 resulted in synergistic tumor regression. These studies demonstrate that integrated genomic and proteomic analyses can be used to identify signaling pathw…

ProteomicsCancer ResearchLung NeoplasmsMAP Kinase Kinase 2MAP Kinase Kinase 1CELLCYCLEAMP-Activated Protein Kinasesmedicine.disease_causeMice0302 clinical medicineAMP-Activated Protein Kinase KinasesCell MovementCarcinoma Non-Small-Cell LungEnzyme InhibitorsNeoplasm MetastasisPhosphorylationLymph nodePhosphoinositide-3 Kinase Inhibitors0303 health sciencesTOR Serine-Threonine KinasesIntracellular Signaling Peptides and ProteinsGenomicsCell cycleProtein-Tyrosine KinasesPenetrance3. Good healthUp-RegulationGene Expression Regulation Neoplasticmedicine.anatomical_structuresrc-Family KinasesOncologySIGNALING030220 oncology & carcinogenesisDrug Therapy CombinationFemaleRNA InterferenceKRASSignal TransductionMice NudeBiologyProtein Serine-Threonine KinasesArticleProto-Oncogene Proteins p21(ras)03 medical and health sciencesCell Line TumorProto-Oncogene ProteinsmedicineCell AdhesionAnimalsHumansEpithelial–mesenchymal transitionProtein Kinase Inhibitors030304 developmental biologyFocal AdhesionsGene Expression ProfilingCell BiologyXenograft Model Antitumor AssaysMice Mutant StrainsGene expression profilingFocal Adhesion Protein-Tyrosine KinasesCancer cellCell TransdifferentiationCancer researchras ProteinsCarcinogenesis
researchProduct

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study

2022

Abstract Background Outcomes after metastasectomy for metastatic colorectal cancer (mCRC) vary with RAS and BRAF mutational status, but their effects on resectability and conversion rates have not been extensively studied. Methods This substudy of the prospective RAXO trial included 906 patients recruited between 2011 and 2018. We evaluated repeated centralised resectability assessment, conversion/resection rates and overall survival (OS), according to RAS and BRAF status. Results Patients included 289 with RAS and BRAF wild-type (RAS and BRAFwt), 529 with RAS mutated (RASmt) and 88 with BRAF mutated (BRAFmt) mCRC. Metastatic prevalence varied between the RAS and BRAFwt/RASmt/BRAFmt groups,…

Proto-Oncogene Proteins B-rafCancer ResearchBEVACIZUMAB3122 Cancerscolorectal cancerbiomarkkerit3121 Internal medicineleikkaushoitoLIVER METASTASESetäpesäkkeetsurgical oncologyKRASHumansmetastasisProspective StudiesFOLFOXIRIpaksusuolisyöpäCancer och onkologiRectal NeoplasmsCOLON-CANCERMetastasectomyennusteetCHEMOTHERAPYOncologysyöpägeenithoitotuloksetCancer and OncologyColonic NeoplasmsMutationSURVIVALsyöpätauditonkologiaColorectal Neoplasmsprognostic markers
researchProduct

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

2010

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with metastatic colorectal carcinoma. Among patients not carrying activating mutations in the KRAS gene, only a limited number will experience tumor response to these therapeutic agents. The role of BRAF mutations in determining resistance to this treatment is emerging through preclinical and clinical studies. Standardization and validation of laboratory mutation analysis is needed to allow an optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Clinical single-arm and randomized studies were conducted both in first-line and refractory settings to evaluate…

Proto-Oncogene Proteins B-rafCancer ResearchPrognosiColorectal cancerCetuximabColorectal Neoplasmmedicine.disease_causeBRAFProto-Oncogene Proteins p21(ras)FOLFOXProto-Oncogene ProteinsAntineoplastic Combined Chemotherapy ProtocolsKRASmedicineHumansPanitumumabEpidermal growth factor receptorBRAF; Cetuximab; Colorectal carcinoma; KRAS; Panitumumab; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Receptor Epidermal Growth Factor; Signal Transduction; ras Proteins; Cancer Research; OncologyneoplasmsProto-Oncogene ProteinClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCetuximabbiologybusiness.industryPanitumumabGeneral Medicineras ProteinPrognosismedicine.diseasedigestive system diseasesOxaliplatinErbB ReceptorsColorectal carcinomaOncologyMutationras ProteinsCancer researchFOLFIRIbiology.proteinReceptor Epidermal Growth FactorKRASPredictive factorColorectal NeoplasmsbusinessHumanSignal Transductionmedicine.drugOncology
researchProduct

Irinotecan or oxaliplatin: Which is the first move for the mate?

2020

Objectives: The aim of the present review is to discuss the potential link between RAS, BRAF and microsatellite instability (MSI) mutational patterns and chemotherapeutic agent efficacy [Irinotecan (IRI) vs. Oxaliplatin (OXA)], and how this can potentially influence the choice of the chemotherapy backbone. Methods: Following a review of the research literature, all pertinent articles published in the core journals were selected for the study. The inclusion criteria regarded relevant clinical and pre-clinical studies on the topic of interest (Relationship of OXA and IRI to KRAS/BRAF mutations and MSI). Results: Excision repair cross complementation group 1 (ERCC1) expression is inhibited by…

Proto-Oncogene Proteins B-rafColorectal cancerPopulationmedicine.disease_causeIrinotecanBiochemistryDNA Mismatch RepairSettore MED/06BRAFDrug DiscoveryKRASMedicineChemotherapyHumanseducationMSIPharmacologyeducation.field_of_studybusiness.industryOrganic ChemistryMicrosatellite instabilitymedicine.diseaseColorectal cancerdigestive system diseasesOxaliplatinIrinotecanOxaliplatinGenes rasMutationCancer researchMolecular MedicineMolecular targetsDNA mismatch repairMicrosatellite InstabilityKRASERCC1businessColorectal Neoplasmsmedicine.drug
researchProduct

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

2020

Abstract Introduction KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the KRAS mutations subtype. Results Over 95% of patients with KRAS mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma…

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyendocrine system diseases[SDV.CAN]Life Sciences [q-bio]/Cancermedicine.disease_causeNSCLClcsh:RC254-28203 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerNon-small cell lung cancerInternal medicinemedicineOverall survivalNon–small cell lung cancerStage (cooking)neoplasms030304 developmental biology0303 health sciencesMutationTransition (genetics)business.industryKRAS mutationmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisConfidence intervaldigestive system diseases3. Good healthrespiratory tract diseasesOncology030220 oncology & carcinogenesisAdenocarcinomaOriginal ArticleKRASbusinessKras mutation
researchProduct

Krasnosel'skiĭ-Schaefer type method in the existence problems

2019

We consider a general integral equation satisfying algebraic conditions in a Banach space. Using Krasnosel'skii-Schaefer type method and technical assumptions, we prove an existence theorem producing a periodic solution of some nonlinear integral equation.

Pure mathematicsCompact operatorApplied MathematicsBanach spaceExistence theoremType (model theory)Nonlinear integral equationNonlinear integral equationCompact operatorIntegral equationSettore MAT/05 - Analisi MatematicaF contractionAlgebraic numberF-contractionAnalysisKrasnosel’skiĭ-schaefer fixed point theoremMathematics
researchProduct

Latvijas arheologu atskaites sesija par 2016.-2017.gada izrakumu rezultātiem: referātu tēzes

2018

Riņņukalna neolīta apmetne - izrakumiRīgas iela Cēsīs - arheoloģiskā izpēteLudzas viduslaiku pils - izpēteGrobiņas pilskalns un senpilsēta - arheoloģiskā izpēte:HUMANITIES and RELIGION::History and philosophy subjects::Archaeology subjects [Research Subject Categories]Ķīšukalns - izrakumiArheoloģiekie izrakumi - LatvijaAntropoloģiskā materiāla paleopataloģiskā izpēteArheoloģiskā izpēte - LatvijaDobeles Livonijas ordeņa pilsdrupasDarvas tecinātava Dundagas pagastā pie Ventnieku mājām - izpēteAlūksnes Tempļa kalns - izrakumiKvartāls Rīgā starp Mārstaļu ielu 11. novembra krastmalu un Minsterejas ielu - arheoloģiskā izpēte
researchProduct

Mīļo, Krastkaln

1927

Īss pārskats par Rīgas Latviešu biedrības Zinību komisijas Valodniecības nodaļā nolasītajiem ziņojumiem

Rīgas Latviešu biedrības Zinību komisijas Valodniecības nodaļa:HUMANITIES and RELIGION [Research Subject Categories]Bandrevičs AnsisLautenbahs JēkabsAbuls PēterisPlāķis JurisKrastkalns AndrejsBalodis FrancisvalodniecībaBasanovičs JonsŠmits PēterisKaudzīte MatīssDr. [Augusts] ZandbergsBīlenšteins Augusts
researchProduct

Rīgas līča un Inčupes krasta erozija pie Saulkrastu Baltās kāpas

2017

Bakalaura darbs ‘’Rīgas līča un Inčupes krasta erozija pie Saulkrastu Baltās kāpas’’ ir pētījums par notiekošajiem ģeoloģiskajiem procesiem Saulkrastu pilsētas piekrastes zonā. Bakalaura darbā ir apskatīta un analizēta zinātniskā literatūra par Latvijas jūras krasta vēsturisko attīstību, to uzbūves veidiem, erozijas riskiem Latvijā un Saulkrastos, kā arī jūras krasta biotopiem un to aizsardzību. Praktiskajā daļā ir analizēts vēsturiskais kartogrāfiskais materiāls, aprakstīti krasta procesi laika posmā no 2016. līdz 2017. gadam un veikti trīs krasta šķērsprofila nivelēšanas mērījumi abpus Inčupes grīvai, pēc kuriem ir analizētas eolā reljefa izmaiņas un kopējā sanešu plūsma pludmalē un primā…

SaulkrastiVides zinātnekrasta procesierozijakrasta šķērsprofila nivelēšana
researchProduct

Admissible perturbations of alpha-psi-pseudocontractive operators: convergence theorems

2015

In the last decades, the study of convergence of fixed point iterative methods has received an increasing attention, due to their performance as tools for solving numerical problems. As a consequence of this fact, one can access to a wide literature on iterative schemes involving different types of operators; see [2, 4, 5]. We point out that fixed point iterative approximation methods have been largely applied in dealing with stability and convergence problems; see [1, 6]. In particular, we refer to various control and optimization questions arising in pure and applied sciences involving dynamical systems, where the problem in study can be easily arranged as a fixed point problem. Then, we …

Settore MAT/08 - Analisi NumericaSettore MAT/05 - Analisi Matematicaalpha-admissible mapping alpha-psi-pseudocontractive operator Hilbert space Krasnoselskij type iterative scheme.
researchProduct